The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called acoramidis (AG10) for the treatment of a rare disease called symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM occurs when a protein in the blood, called transthyretin, clumps together in the blood and accumulates in the heart. This accumulation in the heart is called amyloidosis. Acoramidis binds to transthyretin and by making transthyretin stable, acoramidis may slow the accumulation in the heart. All participants will receive acoramidis by taking 2 pills twice a day.
An Open-Label Extension and Safety Monitoring Study of Acoramidis in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial